{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:54Z","timestamp":1790876694302,"version":"4.1.0"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been found to improve low-grade systemic and tissue inflammation; however, the association between SGLT2 inhibitor use and the incidence of dry eye disease (DED) has not been explored.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the association between SGLT2 inhibitor use and dry eye disease in patients with type 2 diabetes (T2D).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective cohort analysis of the largest multi-institutional electronic medical records database in Taiwan was conducted to identify patients with T2D newly receiving SGLT2 inhibitors or glucagonlike peptide-1 receptor agonists (GLP-1 RAs) from 2016 to 2018. Data analysis was performed from March 1 to May 31, 2022. Propensity scores with inverse probability of treatment weighting were generated to enable homogeneous comparisons between the 2 groups.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Treatment with SGLT2 inhibitors or GLP-1 RAs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incident dry eye disease, which was defined by clinical diagnoses, plus the related drug prescription. Cox proportional hazards regression models were used to estimate hazard ratios with 95% CIs for the risk of DED.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 10\u202f038 and 1077 T2D patients newly receiving SGLT2 inhibitors (mean [SD] age, 59.5 [12.1] years; 5689 [56.7%] men) or GLP-1 RAs (mean [SD] age, 58.5 [41.2] years; 587 [54.5%] men), respectively, were included in the analysis. The incidence of DED was lower in patients newly receiving SGLT2 inhibitors (9.0 events per 1000 person-years) compared with those receiving GLP-1 RAs (11.5 events per 1000 person-years), yielding a hazard ratio of 0.78 (95% CI, 0.68-0.89). Subgroup analyses indicated that the lowered DED risks associated with SGLT2 inhibitors in patients with T2D were similar across different age, sex, blood glucose level, and kidney function groups. Results from the sensitivity analyses (including the propensity score\u2013matching approach, on-treatment analyses, and different follow-up periods of 1, 2, and 3 years) were similar to the main analyses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this study suggest that patients with T2D newly receiving SGLT2 inhibitors may have a lower risk for DED compared with those receiving GLP-1 RAs. Prospective studies are needed to analyze these results.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.32584","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T12:25:31Z","timestamp":1663849531000},"page":"e2232584","source":"Crossref","is-referenced-by-count":50,"title":["Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan"],"prefix":"10.1001","volume":"5","author":[{"given":"Yu-Chen","family":"Su","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horung","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Cheng","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Pharmacy, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaw-Ning","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jui","family":"Hung","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"},{"name":"Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh","family":"Shao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"zoi220928r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition.","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"zoi220928r2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jama.2021.10403","article-title":"Screening for prediabetes and type 2 diabetes: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"326","author":"Jonas","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"zoi220928r3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1586\/eop.10.44","article-title":"Comprehensive review of the effects of diabetes on ocular health.","volume":"5","author":"Skarbez","year":"2010","journal-title":"Expert Rev Ophthalmol"},{"issue":"2","key":"zoi220928r4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","article-title":"Dry eye disease: impact on quality of life and vision.","volume":"1","author":"Uchino","year":"2013","journal-title":"Curr Ophthalmol Rep"},{"key":"zoi220928r5","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8201053","article-title":"Dry eye syndrome in patients with diabetes mellitus: prevalence, etiology, and clinical characteristics.","volume":"2016","author":"Zhang","year":"2016","journal-title":"J Ophthalmol"},{"issue":"5","key":"zoi220928r6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jama.2021.19963","article-title":"Dry eye disease: an update in 2022.","volume":"327","author":"Hakim","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"zoi220928r7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41433-021-01517-x","article-title":"Effects of hormonal contraceptives on dry eye disease: a population-based study.","volume":"36","author":"He","year":"2022","journal-title":"Eye (Lond)"},{"issue":"3","key":"zoi220928r8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report.","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"issue":"2","key":"zoi220928r9","first-page":"240","article-title":"Dry eye: an inflammatory ocular disease.","volume":"9","author":"Hessen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"zoi220928r10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-020-0990-2","article-title":"Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.","volume":"19","author":"Shao","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"zoi220928r11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice.","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"11","key":"zoi220928r12","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1111\/dom.2018.20.issue-11","article-title":"Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component?","volume":"20","author":"Prattichizzo","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"zoi220928r13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcp.v234.1","article-title":"Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways.","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J Cell Physiol"},{"issue":"6","key":"zoi220928r14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006573","article-title":"Chronically elevating circulating ketones can reduce cardiac inflammation and blunt the development of heart failure.","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"1","key":"zoi220928r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101318","article-title":"Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: a multi-institutional cohort study in Taiwan.","volume":"48","author":"Shao","year":"2022","journal-title":"Diabetes Metab"},{"issue":"9","key":"zoi220928r16","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/dom.v23.9","article-title":"Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: a multi-institutional cohort study in Taiwan.","volume":"23","author":"Su","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"zoi220928r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224549","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: a real-world Korean study.","volume":"14","author":"Chung","year":"2019","journal-title":"PLoS One"},{"key":"zoi220928r18","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022.","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"zoi220928r19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","article-title":"Chang Gung Research Database: a multi-institutional database consisting of original medical records.","volume":"40","author":"Tsai","year":"2017","journal-title":"Biomed J"},{"issue":"5","key":"zoi220928r20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.v28.5","article-title":"The Chang Gung Research Database\u2014a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan.","volume":"28","author":"Shao","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi220928r21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12933-021-01406-3","article-title":"Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.","volume":"20","author":"Shao","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"zoi220928r22","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/cpt.v110.6","article-title":"Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-a inhibitors.","volume":"110","author":"Chen","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi220928r23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/cancers14010255","article-title":"RhoGDI2-mediated Rac1 recruitment to filamin A enhances Rac1 activity and promotes invasive abilities of gastric cancer cells.","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"zoi220928r24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jama.2018.0246","article-title":"Association of varicose veins with incident venous thromboembolism and peripheral artery disease.","volume":"319","author":"Chang","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi220928r25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-019-0919-9","article-title":"Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"zoi220928r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2021.12.006","article-title":"Discharge status validation of the Chang Gung Research database in Taiwan.","author":"Huang","journal-title":"Biomed J"},{"key":"zoi220928r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CLEP.S335517","article-title":"Positive Predictive Value of ICD-10 codes for cerebral venous sinus thrombosis in Taiwan\u2019s National Health Insurance Claims database.","volume":"14","author":"Liao","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"4","key":"zoi220928r28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"10296","key":"zoi220928r29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"zoi220928r30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"zoi220928r31","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease.","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"zoi220928r32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.icu.0000512373.81749.b7","article-title":"Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.","volume":"27","author":"Milner","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"zoi220928r33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"zoi220928r34","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1097\/OPX.0000000000000541","article-title":"Risk factors for dry eye syndrome: a retrospective case-control study.","volume":"92","author":"Yang","year":"2015","journal-title":"Optom Vis Sci"},{"issue":"1","key":"zoi220928r35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ophtha.2018.10.023","article-title":"Dry eye syndrome preferred practice pattern.","volume":"126","author":"Akpek","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"zoi220928r36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research.","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"zoi220928r37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"5","key":"zoi220928r38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/aje\/kwq385","article-title":"Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias.","volume":"173","author":"Howe","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"3","key":"zoi220928r39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"zoi220928r40","first-page":"171","article-title":"Vitreous floaters.","volume":"7","author":"Roufail","year":"2006","journal-title":"Compr Ophthalmol Update"},{"issue":"3","key":"zoi220928r41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies.","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"28","key":"zoi220928r42","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.v34.28","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"zoi220928r43","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"zoi220928r44","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"6","key":"zoi220928r45","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/ceo.2018.46.issue-6","article-title":"Association of long-term glycaemic control on tear break-up times and dry eye symptoms in Chinese patients with type 2 diabetes.","volume":"46","author":"Ma","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"zoi220928r46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jtos.2021.03.009","article-title":"Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1\/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model.","volume":"21","author":"Singh","year":"2021","journal-title":"Ocul Surf"},{"issue":"4","key":"zoi220928r47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial.","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"zoi220928r48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdi.v13.1","article-title":"Revisiting the strategies for the pharmacological management of type 2 diabetes\u2014from glycemic control, organ protection, safety to weight reduction.","volume":"13","author":"Li","year":"2022","journal-title":"J Diabetes Investig"},{"issue":"1","key":"zoi220928r49","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"zoi220928r50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jtos.2017.04.001","article-title":"TFOS DEWS II sex, gender, and hormones report.","volume":"15","author":"Sullivan","year":"2017","journal-title":"Ocul Surf"},{"issue":"4","key":"zoi220928r51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00003226-199607000-00001","article-title":"Tear hyperosmolarity in renal dialysis patients asymptomatic for dry eye.","volume":"15","author":"Charlton","year":"1996","journal-title":"Cornea"},{"key":"zoi220928r52","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.2147\/OPTH.S335989","article-title":"The relationship between dry eye in adults with indications for kidney transplantation and influence factors.","volume":"15","author":"Le Trung","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"zoi220928r53","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/00003226-200110000-00005","article-title":"Corneal disease in patients with chronic renal insufficiency undergoing hemodialysis.","volume":"20","author":"Diaz-Couchoud","year":"2001","journal-title":"Cornea"},{"issue":"1","key":"zoi220928r54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12886-020-01395-z","article-title":"The association of dry eye syndrome and psychiatric disorders: a nationwide population-based cohort study.","volume":"20","author":"Liang","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"zoi220928r55","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/aos.2012.90.issue-7","article-title":"Comorbidities of dry eye disease: a nationwide population-based study.","volume":"90","author":"Wang","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"zoi220928r56","first-page":"235","article-title":"The dry eye and diabetes mellitus.","volume":"91","author":"Seifart","year":"1994","journal-title":"Ophthalmologe"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796616\/su_2022_oi_220928_1663261391.76486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T12:25:37Z","timestamp":1663849537000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.32584","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}